Using a dietary supplement to prevent HPV infection persistence
A Pilot Study to Test the Effect of the Association of Epigallocatechin Gallate (EGCG), Folic Acid and Vitamin B12 in Preventing the Persistence of Human Papilloma Virus (HPV) Infection.
NA · Lo.Li.Pharma s.r.l · NCT06285357
This study tests if a dietary supplement with EGCG, folic acid, and vitamin B12 can help people with cervical HPV infections avoid long-term problems that could lead to cancer.
Quick facts
| Phase | NA |
|---|---|
| Study type | Interventional |
| Enrollment | 100 (estimated) |
| Ages | 25 Years to 65 Years |
| Sex | Female |
| Sponsor | Lo.Li.Pharma s.r.l (industry) |
| Locations | 1 site (Modena, Modena) |
| Trial ID | NCT06285357 on ClinicalTrials.gov |
What this trial studies
This study investigates the effects of a dietary supplement containing epigallocatechin gallate (EGCG), folic acid, and vitamin B12 on patients with cervical HPV infections. The goal is to determine whether this combination can help prevent the persistence of HPV, which is known to lead to cervical cancer. Participants will be monitored for changes in HPV status following the intervention. The study aims to provide insights into alternative treatment options for HPV infections.
Who should consider this trial
Good fit: Ideal candidates for this study are individuals who have tested positive for high-risk HPV DNA.
Not a fit: Patients who do not have high-grade squamous intraepithelial lesions (HSIL) may not benefit from this study.
Why it matters
Potential benefit: If successful, this approach could offer a new preventive strategy against the persistence of HPV infections, potentially reducing the risk of cervical cancer.
How similar studies have performed: While there is ongoing research into dietary supplements for HPV treatment, this specific combination of EGCG, folic acid, and vitamin B12 is relatively novel and has not been extensively tested in prior studies.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * HR-HPV DNA test positivity Exclusion Criteria: * No HSIL
Where this trial is running
Modena, Modena
- Azienda Ospedaliero-Universitaria di Modena — Modena, Modena, Italy (RECRUITING)
Study contacts
- Study coordinator: Giovanni Grandi
- Email: giovanni.grandi@unimore.it
- Phone: +390594222830
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.
Conditions: HPV Infection